Redefining Dementia with Lewy Bodies: From Clinical Diagnosis to Targeted Therapies

DESPITE being the second most common degenerative dementia after Alzheimer’s disease, dementia with Lewy bodies (DLB) remains underrecognised, and disease-modifying treatments are not currently available. Experts at the European Academy of Neurology (EAN) Congress 2026 explored the evolving understanding of DLB, including advances in diagnosis, emerging biological definitions of disease, and the expanding therapeutic landscape. The session, held jointly with the European Section of the Movement Disorder Society, was chaired by Irena Rektorová, Masaryk University, Brno, Czechia; and Dag Aarsland, King’s College London, UK.